K
Karin Hardt
Researcher at GlaxoSmithKline
Publications - 46
Citations - 6545
Karin Hardt is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & Vaccine efficacy. The author has an hindex of 24, co-authored 42 publications receiving 4790 citations.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald C. Sadoff,Glenda Gray,An Vandebosch,Vicky Cardenas,Georgi Shukarev,Beatriz Grinsztejn,Paul A. Goepfert,Carla Truyers,Hein Fennema,Bart Spiessens,Kim Offergeld,Gert Scheper,Kimberly L Taylor,Merlin L. Robb,John J. Treanor,Dan H. Barouch,Jeffrey J. Stoddard,Martin Ryser,Mary A. Marovich,Kathleen M. Neuzil,Lawrence Corey,Nancy Cauwenberghs,Tamzin Tanner,Karin Hardt,Javier Ruiz-Guiñazú,Mathieu Le Gars,Hanneke Schuitemaker,Johan Van Hoof,Frank Struyf,Macaya Douoguih +29 more
TL;DR: A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death, in an international, randomized, double-blind, placebo-controlled, phase 3 trial.
Journal ArticleDOI
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Jorma Paavonen,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song-Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Julio Cesar Teixeira,S R Skinner,James Hedrick,Unnop Jaisamrarn,Genara Limson,Suzanne M. Garland,Anne Szarewski,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,Franz X. Bosch,David Jenkins,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Matti Lehtinen,Gary Dubin +26 more
TL;DR: The HPV- 16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.
Journal ArticleDOI
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler,Xavier Castellsagué,Suzanne M. Garland,Anne Szarewski,Jorma Paavonen,Paulo Naud,Jorge Salmerón,Song Nan Chow,D Apter,Henry C Kitchener,Julio Cesar Teixeira,S. Rachel Skinner,Unnop Jaisamrarn,Genara Limson,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,F. Xavier Bosch,Diane M. Harper,Warner K. Huh,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Gary Dubin,Matti Lehtinen +26 more
TL;DR: Data from the end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16/18 vaccine against four oncogenic non-vaccine HPV types-HPV-33, HPV-31, HPV -45, and HPV-51-in different trial cohorts representing diverse groups of women.
Journal ArticleDOI
Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant
Court Pedersen,Tiina Petäjä,Gitte Strauss,H.C. Rumke,Airi Poder,Jan Hendrik Richardus,Bart Spiessens,Dominique Descamps,Karin Hardt,Matti Lehtinen,Gary Dubin +10 more
TL;DR: The findings suggest that HPV vaccination during early adolescence is generally safe, well tolerated, and highly immunogenic, and the implementation of prophylactic HPV vaccination in this age group is supported.
Journal ArticleDOI
Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.
Belén Salinas,Irene Pérez Schael,Alexandre da Costa Linhares,Guillermo M Ruiz Palacios,M. Lourdes Guerrero,Juan Pablo Yarzabal,Yolanda Cervantes,SueAnn Costa Clemens,Silvia Damaso,Karin Hardt,Beatrice De Vos +10 more
TL;DR: Two doses of RIX4414 are highly efficacious, providing cross-protection against any and severe rotavirus gastroenteritis and hospitalization to infants in Latin America and proof of concept that the monovalent G1P1A P[8] human rotav virus vaccine elicits cross- protection against the G9 strain.